CIK 0001782223
- Emerging growth company
Pyxis Oncology, Inc.
Sign in to watch- Ticker
- PYXS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831160910
- Phone
- +1 617-221-9059
- Business address
- 321 HARRISON AVENUE, BOSTON, MA, 02118
- 4 Grant or award Director acquired 35,219 shares (grant or award)
- 4 Grant or award Director acquired 38,741 shares (grant or award)
- 4 Grant or award Director acquired 38,741 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award SVP, Chief Accounting Officer acquired 131,484 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Shares withheld for taxes CFO and COO gave up 36,949 shares (to pay taxes)
- 4 Grant or award Chief Accounting Officer acquired 40,000 shares (grant or award)
- 4 Open-market buy CFO and COO bought 8,000 shares at $1.87 ($14,960)
- 4 Open-market buy Chief Accounting Officer bought 2,500 shares at $1.87 ($4,675)
- 4 Open-market buy CFO and COO bought 6,426 shares at $1.85 ($11,868)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Accounting Officer bought 5,000 shares at $1.77 ($8,850)
- 4 Open-market buy CFO and COO bought 12,000 shares at $1.67 ($20,044)
- 4 Open-market buy Chief Accounting Officer bought 2,500 shares at $1.74 ($4,349)
- 4 Open-market buy CFO and COO bought 5,000 shares at $1.74 ($8,695)
- 4 Open-market sale President and CEO sold 8,641 shares at an average $2.10 ($18,161)
Page 3 of 7 · 126 filings